Komipharm Raises Government Vaccine Supply Contract Value to KRW 10.41 Billion

PUBT · 1d ago
Komipharm Raises Government Vaccine Supply Contract Value to KRW 10.41 Billion
  • Komipharm International corrected its supply contract value to KRW 10.41 billion, an increase of KRW 332 million, on Nov. 4, 2026.
  • The amended Public Procurement Service contract covers 14 animal vaccines, up from 13.
  • The revised value represents 26.16% of 2022 revenue, versus 25.33% previously.
  • The contract runs from Jan. 16, 2024, through Nov. 5, 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Komipharm International Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261104900515), on November 04, 2026, and is solely responsible for the information contained therein.